ReviewJournal of molecular medicine (Berlin, Germany)2008
New angiotensins.
Review in Journal of molecular medicine (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model.International journal of vascular medicine · 2021Review
- Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.Annals of medicine · 2020Article
- Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II-Renin Feedback in Hypertensive Patients.International journal of hypertension · 2020Article
- Many Faces of Renin-angiotensin System - Focus on Eye.The open ophthalmology journal · 2017Review
- Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.American journal of physiology. Heart and circulatory physiology · 2016Review
- Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene.American journal of physiology. Heart and circulatory physiology · 2016Article
- Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.American journal of physiology. Lung cellular and molecular physiology · 2014Article
- ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury.Current hypertension reports · 2014Review
- Cardiovascular effect of angiotensin-(1-12) in the caudal ventrolateral medullary depressor area of the rat.American journal of physiology. Heart and circulatory physiology · 2014Article
- Angiotensin peptides and nitric oxide in cardiovascular disease.Antioxidants & redox signaling · 2013Review
- Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism.American journal of physiology. Heart and circulatory physiology · 2013Article
- Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury.American journal of physiology. Lung cellular and molecular physiology · 2013Article
- Role of the hypothalamic arcuate nucleus in cardiovascular regulation.Autonomic neuroscience : basic & clinical · 2013Review
- Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment.Radiation research · 2012Article
- Angiotensin-(1-7)-mediated signaling in cardiomyocytes.International journal of hypertension · 2012Article
- The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis.Cell cycle (Georgetown, Tex.) · 2011Review
- Angiotensin peptides and lung cancer.Current cancer drug targets · 2011Review
- The hypothalamic arcuate nucleus: a new site of cardiovascular action of angiotensin-(1-12) and angiotensin II.American journal of physiology. Heart and circulatory physiology · 2011Article
- Genetics of salt-sensitive hypertension.Current hypertension reports · 2011Review
- Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.Vascular health and risk management · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Accumulation of a large body of evidence during the past two decades testifies to the complexity of the renin-angiotensin system (RAS). The incorporation of novel enzymatic pathways, resulting peptides, and their corresponding receptors into the biochemical cascade of the RAS provides a better understanding of its role in the regulation of cardiovascular and renal function. Hence, in recent years, it became apparent that the balance between the two opposing effector peptides, angiotensin II and angiotensin-(1-7), may have a pivotal role in determining different cardiovascular pathophysiologies. Furthermore, our recent studies provide evidence for the functional relevance of a newly discovered rat peptide, containing two additional amino acid residues compared to angiotensin I, first defined as proangiotensin-12 [angiotensin-(1-12)]. This review focuses on angiotensin-(1-7) and its important contribution to cardiovascular function and growth, while introducing angiotensin-(1-12) as a potential novel angiotensin precursor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.